Acorda Therapeutics, Inc. ACOR today announced that the United
States Patent and Trademark Office (USPTO) has issued U.S. Patent
Application No. 8,440,703 (“the ‘703 patent”) entitled “Methods of Using
Sustained Release Aminopyridine Compositions.” The ‘703 patent includes
claims directed to methods of improving lower extremity function and
walking and increasing walking speed in patients with multiple sclerosis
(MS) by administering less than 15 mg of sustained release
4-aminopyridine (dalfampridine) twice daily.
The ‘703 patent is set to expire in 2025. This patent is eligible for
listing in the U.S. Food and Drug Administration (FDA) Orange Book.
The ‘703 patent is separate from the two AMPYRA method of use
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in